Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CGON |
---|---|---|
09:32 ET | 1827 | 36.62 |
09:38 ET | 200 | 36.25 |
09:39 ET | 100 | 36.3 |
09:41 ET | 1353 | 36.37 |
09:43 ET | 400 | 36.49 |
09:45 ET | 500 | 36.335 |
09:48 ET | 300 | 36.355 |
09:50 ET | 1840 | 36.51 |
09:52 ET | 490 | 36.425 |
09:54 ET | 100 | 36.51 |
09:56 ET | 500 | 36.42 |
09:57 ET | 1472 | 36.33 |
10:01 ET | 700 | 36.16 |
10:03 ET | 100 | 36.22 |
10:06 ET | 700 | 36.38 |
10:10 ET | 1125 | 36.26 |
10:12 ET | 5109 | 36.17 |
10:14 ET | 502 | 36.13 |
10:15 ET | 5060 | 36.24 |
10:17 ET | 100 | 36.28 |
10:21 ET | 400 | 36.14 |
10:26 ET | 300 | 36.05 |
10:30 ET | 200 | 36.1 |
10:32 ET | 100 | 36.085 |
10:33 ET | 700 | 36.19 |
10:37 ET | 100 | 36.24 |
10:39 ET | 1324 | 36.4 |
10:42 ET | 1359 | 36.31 |
10:44 ET | 310 | 36.27 |
10:46 ET | 300 | 36.17 |
10:53 ET | 300 | 36.26 |
10:57 ET | 2750 | 36 |
11:00 ET | 200 | 36.05 |
11:02 ET | 400 | 36 |
11:04 ET | 5646 | 36.02 |
11:06 ET | 105 | 36.055 |
11:09 ET | 1876 | 36.12 |
11:11 ET | 100 | 36.12 |
11:13 ET | 202 | 36.094 |
11:18 ET | 24249 | 36.27 |
11:20 ET | 951 | 36.26 |
11:22 ET | 730 | 36.22 |
11:24 ET | 1280 | 36.165 |
11:26 ET | 200 | 36.155 |
11:29 ET | 100 | 36.09 |
11:36 ET | 183 | 36.1481 |
11:40 ET | 1810 | 36.14 |
11:42 ET | 699 | 36.23 |
11:45 ET | 700 | 36.38 |
11:47 ET | 1100 | 36.38 |
11:49 ET | 100 | 36.41 |
11:51 ET | 100 | 36.38 |
11:54 ET | 220 | 36.44 |
11:56 ET | 2939 | 36.385 |
12:00 ET | 500 | 36.4 |
12:02 ET | 2400 | 36.405 |
12:03 ET | 800 | 36.415 |
12:05 ET | 5888 | 36.54 |
12:07 ET | 205 | 36.525 |
12:09 ET | 300 | 36.58 |
12:14 ET | 300 | 36.6 |
12:16 ET | 2185 | 36.44 |
12:18 ET | 100 | 36.43 |
12:21 ET | 400 | 36.5 |
12:27 ET | 3166 | 36.605 |
12:30 ET | 400 | 36.565 |
12:39 ET | 100 | 36.6 |
12:43 ET | 100 | 36.65 |
12:45 ET | 100 | 36.61 |
12:48 ET | 2276 | 36.64 |
12:50 ET | 100 | 36.63 |
12:52 ET | 200 | 36.625 |
12:54 ET | 140 | 36.6001 |
12:56 ET | 825 | 36.61 |
12:59 ET | 600 | 36.53 |
01:01 ET | 850 | 36.675 |
01:08 ET | 1436 | 36.68 |
01:12 ET | 100 | 36.72 |
01:15 ET | 400 | 36.68 |
01:17 ET | 1200 | 36.62 |
01:19 ET | 400 | 36.65 |
01:21 ET | 200 | 36.52 |
01:24 ET | 303 | 36.51 |
01:26 ET | 652 | 36.42 |
01:30 ET | 1200 | 36.23 |
01:33 ET | 100 | 36.23 |
01:35 ET | 14451 | 36.42 |
01:37 ET | 1920 | 36.45 |
01:39 ET | 100 | 36.49 |
01:42 ET | 1527 | 36.39 |
01:46 ET | 2786 | 36.375 |
01:48 ET | 400 | 36.385 |
01:50 ET | 279 | 36.43 |
01:53 ET | 100 | 36.445 |
01:55 ET | 600 | 36.49 |
02:00 ET | 1658 | 36.44 |
02:02 ET | 233 | 36.5 |
02:04 ET | 2008 | 36.37 |
02:06 ET | 100 | 36.385 |
02:09 ET | 100 | 36.415 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CG Oncology Inc | 2.4B | -31.2x | --- |
Edgewise Therapeutics Inc | 2.4B | -17.0x | --- |
Structure Therapeutics Inc | 2.4B | -18.9x | --- |
Vera Therapeutics Inc | 2.5B | -20.6x | --- |
SpringWorks Therapeutics Inc | 2.4B | -7.1x | --- |
Immunitybio Inc | 2.5B | -4.0x | --- |
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
---|---|
Revenue (TTM) | $650.0K |
Shares Outstanding | 67.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.17 |
Book Value | $2.91 |
P/E Ratio | -31.2x |
Price/Sales (TTM) | 3,735.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,572.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.